KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Debt to Equity (2016 - 2025)

Jazz Pharmaceuticals has reported Debt to Equity over the past 16 years, most recently at $1.24 for Q4 2025.

  • Quarterly results put Debt to Equity at $1.24 for Q4 2025, down 16.85% from a year ago — trailing twelve months through Dec 2025 was $1.24 (down 16.85% YoY), and the annual figure for FY2025 was $1.24, down 16.85%.
  • Debt to Equity for Q4 2025 was $1.24 at Jazz Pharmaceuticals, down from $1.35 in the prior quarter.
  • Over the last five years, Debt to Equity for JAZZ hit a ceiling of $2.09 in Q3 2022 and a floor of $0.55 in Q1 2021.
  • Median Debt to Equity over the past 5 years was $1.54 (2023), compared with a mean of $1.53.
  • Biggest five-year swings in Debt to Equity: skyrocketed 201.65% in 2022 and later dropped 21.49% in 2023.
  • Jazz Pharmaceuticals' Debt to Equity stood at $1.53 in 2021, then rose by 21.58% to $1.86 in 2022, then fell by 17.59% to $1.53 in 2023, then dropped by 2.39% to $1.49 in 2024, then fell by 16.85% to $1.24 in 2025.
  • The last three reported values for Debt to Equity were $1.24 (Q4 2025), $1.35 (Q3 2025), and $1.45 (Q2 2025) per Business Quant data.